Does the media favor MLTX or CLLS?

In the previous week, MoonLake Immunotherapeutics had 2 more articles in the media than Cellectis. MarketBeat recorded 4 mentions for MoonLake Immunotherapeutics and 2 mentions for Cellectis. Cellectis' average media sentiment score of 0.93 beat MoonLake Immunotherapeutics' score of 0.32 indicating that Cellectis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MoonLake Immunotherapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Cellectis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CLLS or JBIO more profitable?

Jade Biosciences has a net margin of 0.00% compared to Cellectis' net margin of -102.34%. Jade Biosciences' return on equity of -49.11% beat Cellectis' return on equity. Company Net Margins Return on Equity Return on Assets Cellectis -102.34% -94.19% -21.34% Jade Biosciences N/A -49.11% -45.62%

Does the media prefer CLLS or JBIO?

In the previous week, Jade Biosciences had 4 more articles in the media than Cellectis. MarketBeat recorded 6 mentions for Jade Biosciences and 2 mentions for Cellectis. Jade Biosciences' average media sentiment score of 1.30 beat Cellectis' score of 0.93 indicating that Jade Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jade Biosciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CLLS or JANX?

In the previous week, Janux Therapeutics had 3 more articles in the media than Cellectis. MarketBeat recorded 5 mentions for Janux Therapeutics and 2 mentions for Cellectis. Janux Therapeutics' average media sentiment score of 1.36 beat Cellectis' score of 0.93 indicating that Janux Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Janux Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CLLS or GLUE?

In the previous week, Monte Rosa Therapeutics had 6 more articles in the media than Cellectis. MarketBeat recorded 8 mentions for Monte Rosa Therapeutics and 2 mentions for Cellectis. Cellectis' average media sentiment score of 0.93 beat Monte Rosa Therapeutics' score of 0.84 indicating that Cellectis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Monte Rosa Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer CLLS or CRVS?

In the previous week, Cellectis and Cellectis both had 2 articles in the media. Corvus Pharmaceuticals' average media sentiment score of 1.70 beat Cellectis' score of 0.93 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Corvus Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Cellectis (CLLS) Competitors

$3.10 -0.02 (-0.64%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$3.10 0.00 (0.00%)

As of 09/11/2026 07:30 PM Eastern

Compare

CLLS vs. MLTX, JBIO, JANX, GLUE, and CRVS

Should you buy Cellectis stock or one of its competitors? Cellectis's main competitors and comparable companies include MoonLake Immunotherapeutics (MLTX), Jade Biosciences (JBIO), Janux Therapeutics (JANX), Monte Rosa Therapeutics (GLUE), and Corvus Pharmaceuticals (CRVS). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Cellectis compare to MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics (NASDAQ:MLTX) and Cellectis (NASDAQ:CLLS) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

In the previous week, MoonLake Immunotherapeutics had 2 more articles in the media than Cellectis. MarketBeat recorded 4 mentions for MoonLake Immunotherapeutics and 2 mentions for Cellectis. Cellectis' average media sentiment score of 0.93 beat MoonLake Immunotherapeutics' score of 0.32 indicating that Cellectis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MoonLake Immunotherapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Cellectis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MoonLake Immunotherapeutics has a net margin of 0.00% compared to Cellectis' net margin of -102.34%. MoonLake Immunotherapeutics' return on equity of -82.53% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MoonLake Immunotherapeutics	N/A	-82.53%	-58.17%
Cellectis	-102.34%	-94.19%	-21.34%

MoonLake Immunotherapeutics currently has a consensus target price of $24.57, indicating a potential upside of 96.41%. Cellectis has a consensus target price of $7.00, indicating a potential upside of 125.81%. Given Cellectis' stronger consensus rating and higher possible upside, analysts clearly believe Cellectis is more favorable than MoonLake Immunotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MoonLake Immunotherapeutics	3 Sell rating(s)	4 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.41
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

Cellectis has higher revenue and earnings than MoonLake Immunotherapeutics. Cellectis is trading at a lower price-to-earnings ratio than MoonLake Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MoonLake Immunotherapeutics	N/A	N/A	-$227.32M	-$3.84	N/A
Cellectis	$79.59M	3.91	-$67.59M	-$0.65	N/A

MoonLake Immunotherapeutics has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, Cellectis has a beta of 2.92, meaning that its stock price is 192% more volatile than the broader market.

93.9% of MoonLake Immunotherapeutics shares are owned by institutional investors. Comparatively, 63.9% of Cellectis shares are owned by institutional investors. 10.4% of MoonLake Immunotherapeutics shares are owned by company insiders. Comparatively, 16.4% of Cellectis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Cellectis beats MoonLake Immunotherapeutics on 10 of the 15 factors compared between the two stocks.

How does Cellectis compare to Jade Biosciences?

Cellectis (NASDAQ:CLLS) and Jade Biosciences (NASDAQ:JBIO) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.

63.9% of Cellectis shares are owned by institutional investors. 16.4% of Cellectis shares are owned by insiders. Comparatively, 23.1% of Jade Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Cellectis has a beta of 2.92, suggesting that its stock price is 192% more volatile than the broader market. Comparatively, Jade Biosciences has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market.

In the previous week, Jade Biosciences had 4 more articles in the media than Cellectis. MarketBeat recorded 6 mentions for Jade Biosciences and 2 mentions for Cellectis. Jade Biosciences' average media sentiment score of 1.30 beat Cellectis' score of 0.93 indicating that Jade Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jade Biosciences	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Cellectis presently has a consensus target price of $7.00, indicating a potential upside of 125.81%. Jade Biosciences has a consensus target price of $51.75, indicating a potential upside of 189.27%. Given Jade Biosciences' stronger consensus rating and higher probable upside, analysts plainly believe Jade Biosciences is more favorable than Cellectis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

Cellectis has higher revenue and earnings than Jade Biosciences. Jade Biosciences is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$79.59M	3.91	-$67.59M	-$0.65	N/A
Jade Biosciences	N/A	N/A	-$127.41M	-$1.92	N/A

Jade Biosciences has a net margin of 0.00% compared to Cellectis' net margin of -102.34%. Jade Biosciences' return on equity of -49.11% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-102.34%	-94.19%	-21.34%
Jade Biosciences	N/A	-49.11%	-45.62%

Summary

Jade Biosciences beats Cellectis on 9 of the 15 factors compared between the two stocks.

How does Cellectis compare to Janux Therapeutics?

Cellectis (NASDAQ:CLLS) and Janux Therapeutics (NASDAQ:JANX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

63.9% of Cellectis shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 16.4% of Cellectis shares are held by insiders. Comparatively, 7.9% of Janux Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Janux Therapeutics has a net margin of 0.00% compared to Cellectis' net margin of -102.34%. Janux Therapeutics' return on equity of -11.89% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-102.34%	-94.19%	-21.34%
Janux Therapeutics	N/A	-11.89%	-11.13%

Cellectis has higher revenue and earnings than Janux Therapeutics. Janux Therapeutics is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$79.59M	3.91	-$67.59M	-$0.65	N/A
Janux Therapeutics	$10M	104.55	-$113.62M	-$1.64	N/A

Cellectis has a beta of 2.92, suggesting that its share price is 192% more volatile than the broader market. Comparatively, Janux Therapeutics has a beta of 2.53, suggesting that its share price is 153% more volatile than the broader market.

In the previous week, Janux Therapeutics had 3 more articles in the media than Cellectis. MarketBeat recorded 5 mentions for Janux Therapeutics and 2 mentions for Cellectis. Janux Therapeutics' average media sentiment score of 1.36 beat Cellectis' score of 0.93 indicating that Janux Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Janux Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cellectis currently has a consensus price target of $7.00, indicating a potential upside of 125.81%. Janux Therapeutics has a consensus price target of $36.46, indicating a potential upside of 113.23%. Given Cellectis' stronger consensus rating and higher probable upside, equities analysts plainly believe Cellectis is more favorable than Janux Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Janux Therapeutics	2 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Janux Therapeutics beats Cellectis on 8 of the 15 factors compared between the two stocks.

How does Cellectis compare to Monte Rosa Therapeutics?

Cellectis (NASDAQ:CLLS) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

In the previous week, Monte Rosa Therapeutics had 6 more articles in the media than Cellectis. MarketBeat recorded 8 mentions for Monte Rosa Therapeutics and 2 mentions for Cellectis. Cellectis' average media sentiment score of 0.93 beat Monte Rosa Therapeutics' score of 0.84 indicating that Cellectis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Monte Rosa Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cellectis presently has a consensus price target of $7.00, indicating a potential upside of 125.81%. Monte Rosa Therapeutics has a consensus price target of $28.50, indicating a potential upside of 102.56%. Given Cellectis' stronger consensus rating and higher probable upside, equities analysts clearly believe Cellectis is more favorable than Monte Rosa Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Cellectis has a beta of 2.92, indicating that its share price is 192% more volatile than the broader market. Comparatively, Monte Rosa Therapeutics has a beta of 1.5, indicating that its share price is 50% more volatile than the broader market.

Cellectis has a net margin of -102.34% compared to Monte Rosa Therapeutics' net margin of -560.85%. Monte Rosa Therapeutics' return on equity of -43.31% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-102.34%	-94.19%	-21.34%
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%

63.9% of Cellectis shares are held by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 16.4% of Cellectis shares are held by company insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Monte Rosa Therapeutics has higher revenue and earnings than Cellectis. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$79.59M	3.91	-$67.59M	-$0.65	N/A
Monte Rosa Therapeutics	$123.67M	9.71	-$38.63M	-$1.76	N/A

Summary

Cellectis beats Monte Rosa Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Cellectis compare to Corvus Pharmaceuticals?

Cellectis (NASDAQ:CLLS) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

63.9% of Cellectis shares are held by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 16.4% of Cellectis shares are held by company insiders. Comparatively, 19.7% of Corvus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

In the previous week, Cellectis and Cellectis both had 2 articles in the media. Corvus Pharmaceuticals' average media sentiment score of 1.70 beat Cellectis' score of 0.93 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corvus Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Cellectis has a beta of 2.92, indicating that its stock price is 192% more volatile than the broader market. Comparatively, Corvus Pharmaceuticals has a beta of 0.87, indicating that its stock price is 13% less volatile than the broader market.

Corvus Pharmaceuticals has a net margin of 0.00% compared to Cellectis' net margin of -102.34%. Corvus Pharmaceuticals' return on equity of -36.15% beat Cellectis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectis	-102.34%	-94.19%	-21.34%
Corvus Pharmaceuticals	N/A	-36.15%	-33.62%

Corvus Pharmaceuticals has lower revenue, but higher earnings than Cellectis. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectis	$79.59M	3.91	-$67.59M	-$0.65	N/A
Corvus Pharmaceuticals	N/A	N/A	-$15.28M	-$0.61	N/A

Cellectis currently has a consensus target price of $7.00, indicating a potential upside of 125.81%. Corvus Pharmaceuticals has a consensus target price of $33.33, indicating a potential upside of 158.20%. Given Corvus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Corvus Pharmaceuticals is more favorable than Cellectis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectis	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Corvus Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Corvus Pharmaceuticals beats Cellectis on 9 of the 14 factors compared between the two stocks.

Get Cellectis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLLS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLLS vs. The Competition

Export

Metric	Cellectis	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$311.05M	$3.84B	$7.12B	$12.72B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	-4.77	14.25	275.24	25.29
Price / Sales	3.91	1,473.06	655.99	98.94
Price / Cash	N/A	106.68	77.04	51.44
Price / Book	4.08	15.12	10.33	6.20
Net Income	-$67.59M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-4.32%	-4.34%	-3.32%	-2.35%
1 Month Performance	5.44%	-0.02%	-0.41%	-2.77%
1 Year Performance	7.27%	40.64%	19.21%	7.63%

Cellectis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLLS Cellectis	1.9478 of 5 stars	$3.10 -0.6%	$7.00 +125.8%	+4.0%	$311.05M	$79.59M	N/A	290	High Trading Volume
MLTX MoonLake Immunotherapeutics	1.8768 of 5 stars	$14.94 -0.5%	$24.57 +64.5%	-77.0%	$1.27B	N/A	N/A	2
JBIO Jade Biosciences	2.521 of 5 stars	$19.76 -0.7%	$51.75 +161.9%	+130.5%	$1.26B	N/A	N/A	20	News Coverage Analyst Downgrade
JANX Janux Therapeutics	3.5958 of 5 stars	$19.99 -1.3%	$36.46 +82.4%	-31.9%	$1.22B	$10M	N/A	30	Positive News
GLUE Monte Rosa Therapeutics	2.4836 of 5 stars	$14.17 +2.4%	$28.50 +101.1%	+187.7%	$1.21B	$123.67M	N/A	90	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLLS) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cellectis (CLLS) Competitors

CLLS vs. MLTX, JBIO, JANX, GLUE, and CRVS

How does Cellectis compare to MoonLake Immunotherapeutics?

Summary

How does Cellectis compare to Jade Biosciences?

Summary

How does Cellectis compare to Janux Therapeutics?

Summary

How does Cellectis compare to Monte Rosa Therapeutics?

Summary

How does Cellectis compare to Corvus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLLS vs. The Competition

Cellectis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cellectis (CLLS) Competitors

CLLS vs. MLTX, JBIO, JANX, GLUE, and CRVS

How does Cellectis compare to MoonLake Immunotherapeutics?

Does the media favor MLTX or CLLS?

Is MLTX or CLLS more profitable?

Do analysts rate MLTX or CLLS?

Which has stronger earnings and valuation, MLTX or CLLS?

Which has more risk & volatility, MLTX or CLLS?

Do insiders & institutionals believe in MLTX or CLLS?

Summary

How does Cellectis compare to Jade Biosciences?

Do institutionals & insiders have more ownership in CLLS or JBIO?

Which has more risk and volatility, CLLS or JBIO?

Does the media prefer CLLS or JBIO?

Do analysts recommend CLLS or JBIO?

Which has stronger valuation & earnings, CLLS or JBIO?

Is CLLS or JBIO more profitable?

Summary

How does Cellectis compare to Janux Therapeutics?

Do institutionals and insiders hold more shares of CLLS or JANX?

Is CLLS or JANX more profitable?

Which has higher valuation & earnings, CLLS or JANX?

Which has more risk & volatility, CLLS or JANX?

Does the media favor CLLS or JANX?

Do analysts recommend CLLS or JANX?

Summary

How does Cellectis compare to Monte Rosa Therapeutics?

Does the media prefer CLLS or GLUE?

Do analysts recommend CLLS or GLUE?

Which has more volatility and risk, CLLS or GLUE?

Is CLLS or GLUE more profitable?

Do insiders & institutionals believe in CLLS or GLUE?

Which has better earnings & valuation, CLLS or GLUE?

Summary

How does Cellectis compare to Corvus Pharmaceuticals?

Do institutionals and insiders believe in CLLS or CRVS?

Does the media prefer CLLS or CRVS?

Which has more risk & volatility, CLLS or CRVS?

Is CLLS or CRVS more profitable?

Which has preferable valuation & earnings, CLLS or CRVS?

Do analysts recommend CLLS or CRVS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLLS vs. The Competition

Cellectis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools